OxThera, Inc.: Pivotal Study is Being Conducted with Oxabact(TM) for the Treatment of Primary Hyperoxaluria

STOCKHOLM, Sweden--(BUSINESS WIRE)--OxThera today announced that all 42 patients have been enrolled in their pivotal phase II/III study using Oxabactâ„¢ for the treatment of Primary Hyperoxaluria. Results from this multicenter study will be presented during Q4 of 2008 and be used to file for licensure in EU, US and the rest of the world.

Back to news